Tislelizumab,Sorafenib
BeiGene,bayer,novartis
['lba3', 'lba36', 'novartis']
today at #esmo22, dr masatoshi kudo presents final analysis data from a phase iii trial comparing a pd-1 inhibitor vs a tki in patients with unresectable #hepatocellularcarcinoma. abstract lba36
Committed to providing medical & scientific disease education information to healthcare professionals. See our community guidelines: https://t.co/pj8hG1sQAu